The Trust Layer for Market Analysts

Eli Lilly and Company (LLY) is showing several negative technical signals, including a wider and falling trend, with short-term and long-term moving averages indicating a more negative forecast. A recent downgrade in analyst ratings and concerns around its obesity franchise have contributed to this outlook. The stock's trajectory suggests a potential further decrease in value, with resistances at $984.46 and $1,020.22. Conversely, a break above these levels could signal a shift. However, the prevailing trend indicates a bearish outlook, with recent price action confirming this sentiment.